Olema Pharmaceuticals (OLMA) Competitors

Harrow (NASDAQ:HROW) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Is HROW or OLMA more profitable?

Olema Pharmaceuticals has a net margin of 0.00% compared to Harrow's net margin of -10.19%. Harrow's return on equity of -25.01% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-10.19%	-25.01%	-4.27%
Olema Pharmaceuticals	N/A	-42.31%	-38.32%

Which has stronger valuation & earnings, HROW or OLMA?

Harrow has higher revenue and earnings than Olema Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$212.86M	6.24	-$17.48M	-$0.56	-64.63
Olema Pharmaceuticals	N/A	N/A	-$129.47M	-$2.01	-2.34

Does the media refer more to HROW or OLMA?

In the previous week, Harrow had 6 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 7 mentions for Harrow and 1 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.89 beat Harrow's score of 0.90 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Harrow	Positive
Olema Pharmaceuticals	Very Positive

Do insiders and institutionals have more ownership in HROW or OLMA?

72.8% of Harrow shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 15.2% of Harrow shares are held by company insiders. Comparatively, 16.4% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has more risk & volatility, HROW or OLMA?

Harrow has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.

Do analysts prefer HROW or OLMA?

Harrow presently has a consensus price target of $63.83, suggesting a potential upside of 76.38%. Olema Pharmaceuticals has a consensus price target of $24.50, suggesting a potential upside of 420.17%. Given Olema Pharmaceuticals' higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Olema Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Harrow and Olema Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.